Timothy K. Hart

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Helai P. Mohammad, Kimberly N. Smitheman, Chandrashekhar D. Kamat et al. · Cancer Cell · 2015 · 498 citations · Full text

Oncogenic Agent, Medicine, Epigenetic Change +9

Physical, Morphological and Functional Differences between pH 5.8 and 7.4 Aggregates of the Alzheimer's Amyloid Peptide A β

Stephen Wood, Beverly E. Maleeff, Timothy K. Hart et al. · Journal of Molecular Biology · 1996 · 338 citations

Neurodegenerative Diseases, Alzheimer's Disease, Functional Differences +8

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien et al. · Cancer Cell · 2019 · 333 citations · Full text

Cancer Research, Mtap Loss, Medicine +10

In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-γ Agonist Rosiglitazone

Tianli Yue, Jun Chen, Weike Bao et al. · Circulation · 2001 · 295 citations · Full text

Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation

Jia Yi Fong, Luca Pignata, Pierre-Alexis Goy et al. · Cancer Cell · 2019 · 270 citations · Full text

Rna Processing, Transcriptional Regulation, Engineering +13